^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AryoTrust (trastuzumab biosimilar)

    i
    Other names: TA4415V
    Company:
    AryoGen Pharmed, Inno Bio
    Drug class:
    HER2 inhibitor
    Related drugs:
    4d
    Analytical Physicochemical and Functional Studies to Compare AryoTrust, a Follow-On Biologics, with the Originator Trastuzumab (Herceptin). (PubMed, Pharmaceutics)
    The integrated analytical and functional data support the biosimilarity of AryoTrust to the reference product Herceptin, which has been marketed and used in Iraq. This study provides real-world scientific evidence supporting confidence in the quality and comparability of this trastuzumab biosimilar and reduces any doubt in the product and at the same time emphasizes the value of independent post-marketing biosimilarity assessments.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • AryoTrust (trastuzumab biosimilar)
    over1year
    Safety evaluation of the trastuzumab biosimilar in Iranian women with HER2-positive breast cancer undergoing adjuvant chemotherapy: a post-marketing surveillance. (PubMed, Expert Opin Drug Saf)
    The results demonstrate that this trastuzumab biosimilar is a generally well-tolerated and safe treatment for HER2-positive BC. www.clinicaltrials.gov identifier is NCT06021379.
    P4 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    AryoTrust (trastuzumab biosimilar)
    over2years
    AryoTrust® (Trastuzumab) Safety Study (clinicaltrials.gov)
    P=N/A, N=597, Completed, AryoGen Pharmed Co.
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • AryoTrust (trastuzumab biosimilar)
    over5years
    Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer (clinicaltrials.gov)
    P3, N=108, Completed, AryoGen Pharmed Co. | Recruiting --> Completed
    Clinical • Trial completion • Head-to-Head
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    docetaxel • doxorubicin hydrochloride • AryoTrust (trastuzumab biosimilar)